No Data
REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights
BofA Securities Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $22
Bank of America Securities Reaffirms Their Buy Rating on RegenXBio (RGNX)
Gene Therapy Developers Rise on Comments From FDA's Makary
Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price Following 29% Dive
REGENXBIO Is Maintained at Neutral by Goldman Sachs